Wall Street equity analysts covering Allogene Therapeutics (ALLO) maintain a median 12-month consensus price target hovering around $9.00 per share, with individual institutional forecasts ranging from a low target of $4.00 to a bullish high estimate of $14.00. These targets reflect ongoing assessments of its clinical pipeline progress and balance sheet capital runway.